Source: Fobi.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Fobi (FOBI) signed a five-year C$10 million licensing agreement with Canadian beverage manufacturing company, BevWorks Brands
  • BevWorks will receive licenses to various Fobi technologies, including real-time data processing and artificial intelligence applications, mobile wallet pass technology, patented IoT hardware, advanced analytics and forecasting technology, as well as the Fobi Data Exchange
  • Fobi’s platform will allow BevWorks to make 100-per-cent data-driven decisions that optimize product selection and development, sales and marketing strategies, distribution models and strategic acquisitions
  • Vancouver-based Fobi is an AI and data intelligence company that leverages and monetizes customer data by powering personalized customer experiences
  • Fobi AI (FOBI) opened today at $0.495

Fobi (FOBI) has signed a five-year C$10 million licensing agreement with BevWorks Brands.

BevWorks is a Canadian beverage manufacturer that specializes in in-house production across various markets, including alcohol, beer, RTD liquor and alcohol replacement.

Fobi will provide BevWorks with access to various technologies, including artificial intelligence and real-time data processing, as well as advanced analytics and forecasting technology.

The technologies will enable BevWorks to make data-driven decisions in areas such as product selection and development, sales and marketing strategies, distribution models and strategic acquisitions.

The license agreement is part of Fobi’s growth and monetization strategy, which aims to address high-value industries through licensing and joint venture opportunities.

Vancouver-based Fobi is an AI and data intelligence company that leverages and monetizes customer data by powering personalized customer experiences.

Fobi AI (FOBI) opened today at $0.495.


More From The Market Herald
Neuralink - Founder, Elon Musk.

" Neuralink brain chips approved for human trials

Elon Musk’s Neuralink, a brain implant firm, has received regulatory approval for U.S. human trials.

" @ the Bell: TSX snaps three-day losing skid

After a series of sessions in the red, Canada’s main stock index closed out Friday trading in the green as commodity prices nudged

" Marvell stock spikes 30 per cent on Q1 news  

Marvell Technology (NASDAQ:MRVL) shares rose more than 30 per cent Friday.